ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GENF Genflow Biosciences Plc

1.55
0.00 (0.00%)
22 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Genflow Biosciences Plc LSE:GENF London Ordinary Share GB00BP2C3V08 ORD GBP0.0003
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 1.55 28,575 08:00:00
Bid Price Offer Price High Price Low Price Open Price
1.50 1.60 1.55 1.55 1.55
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 487k -1.34M -0.0046 -3.37 4.53M
Last Trade Time Trade Type Trade Size Trade Price Currency
15:40:50 O 46 1.60 GBX

Genflow Biosciences (GENF) Latest News

Genflow Biosciences (GENF) Discussions and Chat

Genflow Biosciences Forums and Chat

Date Time Title Posts
16/4/202420:56Genflow Biosciences plc 20221,031
14/6/202318:08Old age a thing of the past?61
15/4/202211:31US SEC indicts key shareholder-
01/2/202211:45Welcome3

Add a New Thread

Genflow Biosciences (GENF) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
14:40:521.60460.74O
12:15:541.5415,000231.00O
12:11:411.604507.20O
12:11:401.601,55424.86O
12:11:401.50701.05O

Genflow Biosciences (GENF) Top Chat Posts

Top Posts
Posted at 22/4/2024 09:20 by Genflow Biosciences Daily Update
Genflow Biosciences Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GENF. The last closing price for Genflow Biosciences was 1.55p.
Genflow Biosciences currently has 292,506,618 shares in issue. The market capitalisation of Genflow Biosciences is £4,533,853.
Genflow Biosciences has a price to earnings ratio (PE ratio) of -3.37.
This morning GENF shares opened at 1.55p
Posted at 08/2/2024 16:57 by moneymunch
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,475 followers
4h

We here at Genflow Biosciences (LON:GENF) (OTCQB:GENFF) are proud of the accomplishments we’ve made in 2023 and look forward to an even more prosperous 2024.

We’d like to share our Year-End Review with you, as well as what we are most excited for in the upcoming year:

#healthspan #longevity
Posted at 28/1/2024 19:07 by kubera369
At the end of the day it's all about making money and with my experience here I rather gamble all in BiRD and if the share price here is still low as it is then all good Genflow is a winner but only when the FDA announce that Ageing is a disease and the NASH trials are still well over 12 months away.Cannot deal with the daily drip down of share price here We had no news since last year Aoril spike in share price until just recent and the share price again has dipped down It's crazy and I'm taking a calculated gamble and am certainly not going to get my wings clipped Good luck here and I may be back
Posted at 28/1/2024 09:04 by kubera369
Whilst we are all sat here waiting I am going to recommend a fantastic share tip with you all if your interestedTICKER : BIRD (BLACKBIRD)last year I almost doubled my holdings in Genflow by buying bombed out winners and BIRD is an amazing opportunity imoGenflow has a knack get to.a point where there are hardly any trades happening and share price does nothing.It's all about volume and investors interest that moves share prices Don't miss out and have a great day
Posted at 27/1/2024 08:49 by moneymunch
Updates

View organization page for Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,455 followers
20h

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is excited to announce the release of its Annual 2023 Year in Review. This past year, we have achieved significant progress in our primary research areas in Non-Alcoholic Steatohepatitis (NASH) and Werner Syndrome.

Alongside these achievements, we have also made considerable strides in fortifying our corporate structure, enhancing our financial stability, and expanding our market presence to North America.

Read it here:

#longevity #NASH #Werner #SIRT6 #ageing #Genflow #GENF
Posted at 24/10/2023 18:49 by kubera369
Can eric please tell us patient share holders what he is up to?Have you seen the pathetic paltry share price Eric ?The share price has nose dived since the U.S listing Where is the value for us share holders ?You have seen the share price plummet from over 10p to where it is today Can we have some answers Wd are the share holders and the supporters and so far we have been misled by you
Posted at 13/6/2023 07:02 by moneymunch
RNS Number : 4646C
Genflow Biosciences PLC
13 June 2023




Genflow Biosciences Plc



("Genflow" or "the Company")



Anti-Ageing Company, Genflow Biosciences, Announces Listing on OTCQB Venture Market

in addition to its LSE Main Market Listing



Genflow has 3 Gene Therapies in Development Seeking to Treat NASH and Werner Syndrome



Genflow Biosciences Plc ("Genflow" or "the Company") is pleased to announce that, after a successful application process, its Ordinary Shares ("Ordinary Shares") begin trading on the OTCQB Venture Market in the United States ("US") today under the symbol GENFF. Genflow will continue to trade on the London Stock Exchange ("LSE") Main Market under the symbol GENF, and, importantly, the onboarding to this additional U.S. securities trading platform does not involve any capital raise. The new U.S. trading facility expands access to a broader pool of investors and enables investors in the United States to trade during U.S. trading hours and in U.S. dollars.



Eric Leire, CEO of Genflow, expressed his excitement about this significant achievement, stating, "We are thrilled to announce that Genflow Biosciences has been admitted to trading on the OTCQB Venture Market in the United States. This move not only expands our reach to a larger investor base and has the potential to enhance liquidity for our shares, but also reinforces our unwavering commitment to our primary listing on the prestigious London Stock Exchange."



Tamara Joseph, Chair of the Board, also expressed her enthusiasm on behalf of the Board of Directors, saying, "Genflow is developing gene therapies that could address an important source of many global illnesses: aging. As the Company moves into Phase I/II clinical trials to treat potentially the orphan condition Werner Syndrome, which causes premature aging, and NASH, a liver disease that affects an estimated 35 million people around the world, it is the right time to retain our London Stock Exchange listing while adding easier access for US investors."



Further information on Genflow's application and the OTCQB market is below:



As a Foreign Private Issuer, Genflow's admission to the OTC Markets is subject to meeting the requirements for OTCQB, which apply to international reporting companies. This includes fulfilling the criteria for exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting. The Rule 12g3-2(b) exemption includes the disclosure obligation to ensure that certain information made public or distributed under home market regulations is made publicly available on the Company's website or other electronic information delivery system in English. Thus, the Company will have no additional reporting obligations and incur minimal ongoing costs; admission to the OTC Markets is subject to meeting the requirements for OTCQB, which apply to international reporting companies.



This includes fulfilling the criteria for exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting. Under this exemption, the Company must ensure that information made public or distributed under its home market regulations is made available to the public on its website or another electronic information delivery system in English. Consequently, Genflow will have no additional reporting obligations and will incur minimal ongoing costs compared to traditional major exchanges.



As a verified market, the OTCQB offers transparent trading for companies that have met a minimum bid price test, are current in their financial reporting and have undergone an annual verification and management certification process.



The cross-trading facility is provided through OTC Markets Group Inc., located in New York. OTC Markets operates the world's largest electronic interdealer quotation system for US broker-dealers and offers multiple media channels to increase the visibility of OTC-listed companies. Online brokers such as Ameritrade, Fidelity Investments, Tradestation, Charles Schwab and E-trade all offer OTCQB trades. US investors can find real-time quotes, market information and access current company news and developments on a BSF page on the OTC Markets website at www.otcmarkets.com.



Genflow appointed the corporate securities law firm Galanopoulos & Company as its OTCQB Sponsor to support its onboarding to the OTCQB Venture Market.



Additional information about the OTCQB market can be found at: www.otcmarkets.com/learn/market-101



The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
Posted at 06/6/2023 19:06 by stark industries
Here's why this UK BioTech stock could potentially be set to rise imminently

Today I’m going to tell you about a revolutionary biotech startup that I previously tipped when it was trading at 2p back in November.

A company I believe is set to explode and has the potential to rise significantly in the near term.

What justifies such a bold prediction?


This company may hold the keys to the cure for aging...

The name of the company is Genflow Biosciences and it trades under the ticker (GENF) on the London stock exchange.

Consider that the biotech market is expected to reach USD 2.44 trillion by 2028 and expand at a CAGR of 15.83% until then.*

The demand for longevity is limitless, and the first companies that succeed in supplying the disruptive technologies that unlock it will capture the lion’s share of those trillions.

But before I go any further, let me ask you something…

Have you heard of the freshly minted biotech mega-startup that received $3 billion in backing in a single day?

According to Forbes, Altos Labs likely holds the world record for financing of any start-up by an order of magnitude or more.

With reports of early investments from entrepreneurial juggernaut Jeff Bezos and renowned info-tech investor Yuri Milner, Altos Labs is a likely contender for a top spot in the race to reverse aging and revolutionize medicine.

But backing from big names isn’t the only ace up the sleeve of Altos Labs…

The company has built an executive dream team of industry experts and scientific luminaries.

Among those reported to be joining the ambitious roster is none other than the Nobel prize winner for the discovery of reprogramming.


What is reprogramming and why is it important you might ask?

Shinya Yamanaka won his Nobel prize for discovering how to transform ordinary adult skin cells into any cell in the human body.

Need a new liver? Tired of living with Parkinson’s? Want your eyesight back?

Yamanaka’s research is key to engineering the regenerative medicine that will one day be responsible for replacing and repairing damaged organs and tissues.

With a deluge of capital and a hot shot team to employ it efficiently, Altos Labs is poised to accomplish its mission statement, “to restore cell health and resilience to reverse disease, injury, and disabilities that occur throughout life.”


But what does all of this have to do with Genflow Biosciences potentially significant rise in value?

I’m going to tell you, but first, let’s get some background.

Genflow Biosciences is challenging the aging process with exclusive patents to the leading longevity technology from the University of Rochester (US).

Okay, but why should we expect such sudden exponential growth.

The answer lies in a 2013 paper published in a highly regarded journal entitled “The Hallmarks of Ageing”...

To put it simply, the paper outlines 9 hallmarks of aging that provide a framework for prolonging human life. This roadmap to longevity spawned numerous biotech companies that used it as a roadmap for their R&D.


But even the companies regarded as the cream-of-crop are at a disadvantage…

They tend to focus on a single hallmark of aging. To quote Eric Leire, the company’s chief executive, “You’ve only solved one-ninth of the problem with this approach.”

Genflow Biosciences takes a holistic approach by targeting 4 of the 9 hallmarks directly, in addition to 2 indirectly. They are able to do this by focusing on the SIRT6 gene. This gene’s over expression has proven to extend the lives of healthy mice, winning it the title of the “master regulator of aging”.

This novel research has allowed the company to capture alluring patents, which brings us back to Altos Labs…

If anyone wants this IP they would have to purchase the company at a significant premium to the current share price or enter a licensing agreement.

Altos Labs opened only last year, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition.

It stands to reason that Genflow Biosciences could become an attractive acquisition target for a mega-tech startup such as Altos Labs.

Markets are extremely sensitive to takeovers, and the mere rumour of a potential acquisition could result in a drastic increase in Genflow's significantly undervalued share price


News like this could pop at any second. Launching Genflow Biosciences into the spotlight at any time this year.

This is a highly competitive industry and players with deep pockets see Genflow Biosciences’ IP as their ticket to the top of the market. If it’s not Altos Labs, then surely there will be another.

That is why I am recommending readers take a close look at it right now.

The company is currently eyeing a listing in other markets and a US listing may be on the horizon.


If I were to bet on the next big biotech stock story, Genflow BioSciences would be it.






Altos Labs opened only last year, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition.

It stands to reason that Genflow Biosciences could become an attractive acquisition target for a mega-tech startup such as Altos Labs.

Markets are extremely sensitive to takeovers, and the mere rumour of a potential acquisition could result in a drastic increase in Genflow's significantly undervalued share price



I suggest you all read through the attached link.
Mind Blowing as to how low our MCap is compared to our U.S neighbours
Target was 16p upon IPO and now with all the latest positives and the announcement of the U.S listing......expecting the share price to go to a realistic Mcap
conservative X 10 Share Price from current position !!!
Posted at 06/6/2023 18:30 by stark industries
Here's why this UK BioTech stock could potentially be set to rise imminently

Today I’m going to tell you about a revolutionary biotech startup that I previously tipped when it was trading at 2p back in November.

A company I believe is set to explode and has the potential to rise significantly in the near term.

What justifies such a bold prediction?



This company may hold the keys to the cure for aging...

The name of the company is Genflow Biosciences and it trades under the ticker (GENF) on the London stock exchange.

Consider that the biotech market is expected to reach USD 2.44 trillion by 2028 and expand at a CAGR of 15.83% until then.*

The demand for longevity is limitless, and the first companies that succeed in supplying the disruptive technologies that unlock it will capture the lion’s share of those trillions.

But before I go any further, let me ask you something…

Have you heard of the freshly minted biotech mega-startup that received $3 billion in backing in a single day?

According to Forbes, Altos Labs likely holds the world record for financing of any start-up by an order of magnitude or more.

With reports of early investments from entrepreneurial juggernaut Jeff Bezos and renowned info-tech investor Yuri Milner, Altos Labs is a likely contender for a top spot in the race to reverse aging and revolutionize medicine.

But backing from big names isn’t the only ace up the sleeve of Altos Labs…

The company has built an executive dream team of industry experts and scientific luminaries.

Among those reported to be joining the ambitious roster is none other than the Nobel prize winner for the discovery of reprogramming.



What is reprogramming and why is it important you might ask?

Shinya Yamanaka won his Nobel prize for discovering how to transform ordinary adult skin cells into any cell in the human body.

Need a new liver? Tired of living with Parkinson’s? Want your eyesight back?

Yamanaka’s research is key to engineering the regenerative medicine that will one day be responsible for replacing and repairing damaged organs and tissues.

With a deluge of capital and a hot shot team to employ it efficiently, Altos Labs is poised to accomplish its mission statement, “to restore cell health and resilience to reverse disease, injury, and disabilities that occur throughout life.”



But what does all of this have to do with Genflow Biosciences potentially significant rise in value?

I’m going to tell you, but first, let’s get some background.

Genflow Biosciences is challenging the aging process with exclusive patents to the leading longevity technology from the University of Rochester (US).

Okay, but why should we expect such sudden exponential growth.

The answer lies in a 2013 paper published in a highly regarded journal entitled “The Hallmarks of Ageing”...

To put it simply, the paper outlines 9 hallmarks of aging that provide a framework for prolonging human life. This roadmap to longevity spawned numerous biotech companies that used it as a roadmap for their R&D.



But even the companies regarded as the cream-of-crop are at a disadvantage…

They tend to focus on a single hallmark of aging. To quote Eric Leire, the company’s chief executive, “You’ve only solved one-ninth of the problem with this approach.”

Genflow Biosciences takes a holistic approach by targeting 4 of the 9 hallmarks directly, in addition to 2 indirectly. They are able to do this by focusing on the SIRT6 gene. This gene’s overexpression has proven to extend the lives of healthy mice, winning it the title of the “master regulator of aging”.

This novel research has allowed the company to capture alluring patents, which brings us back to Altos Labs…

If anyone wants this IP they would have to purchase the company at a significant premium to the current share price or enter a licensing agreement.

Altos Labs opened only last year, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition.

It stands to reason that Genflow Biosciences could become an attractive acquisition target for a mega-tech startup such as Altos Labs.

Markets are extremely sensitive to takeovers, and the mere rumour of a potential acquisition could result in a drastic increase in Genflow's significantly undervalued share price



News like this could pop at any second. Launching Genflow Biosciences into the spotlight at any time this year.

This is a highly competitive industry and players with deep pockets see Genflow Biosciences’ IP as their ticket to the top of the market. If it’s not Altos Labs, then surely there will be another.

That is why I am recommending readers take a close look at it right now.

The company is currently eyeing a listing in other markets and a US listing may be on the horizon.



If I were to bet on the next big biotech stock story, Genflow BioSciences would be it.
Posted at 11/4/2023 10:57 by stark industries
Here's why this UK BioTech stock could potentially be set to rise imminently

Authored by Joe Neighbour (MSTA)

Joe started his career in financial services with HSBC at 18 years old before moving into broking arena at several small to medium-size firms. It was here that Joe gained vast experience in dealing with high net worth individuals and providing wealth solutions.

He began to develop a passion for technical analysis and this desire to learn more about markets sent him down a path of trading. Joe became involved in trading markets just before the 2008 financial crisis and had to quickly adapt to some very challenging conditions.

Joe is a Member of the Society of Technical Analysis (MSTA) and Chartered Fellow (CISI). He has 15+ years’ experience in financial markets across a variety of roles including broking, portfolio managing, and analysis.

Today I’m going to tell you about a revolutionary biotech startup that I previously tipped when it was trading at 2p back in November.

A company I believe is set to explode and has the potential to rise significantly in the near term.

What justifies such a bold prediction?



This company may hold the keys to the cure for aging...

The name of the company is Genflow Biosciences and it trades under the ticker (GENF) on the London stock exchange.

Consider that the biotech market is expected to reach USD 2.44 trillion by 2028 and expand at a CAGR of 15.83% until then.*

The demand for longevity is limitless, and the first companies that succeed in supplying the disruptive technologies that unlock it will capture the lion’s share of those trillions.

But before I go any further, let me ask you something…

Have you heard of the freshly minted biotech mega-startup that received $3 billion in backing in a single day?

According to Forbes, Altos Labs likely holds the world record for financing of any start-up by an order of magnitude or more.

With reports of early investments from entrepreneurial juggernaut Jeff Bezos and renowned info-tech investor Yuri Milner, Altos Labs is a likely contender for a top spot in the race to reverse aging and revolutionize medicine.

But backing from big names isn’t the only ace up the sleeve of Altos Labs…

The company has built an executive dream team of industry experts and scientific luminaries.

Among those reported to be joining the ambitious roster is none other than the Nobel prize winner for the discovery of reprogramming.



What is reprogramming and why is it important you might ask?

Shinya Yamanaka won his Nobel prize for discovering how to transform ordinary adult skin cells into any cell in the human body.

Need a new liver? Tired of living with Parkinson’s? Want your eyesight back?

Yamanaka’s research is key to engineering the regenerative medicine that will one day be responsible for replacing and repairing damaged organs and tissues.

With a deluge of capital and a hot shot team to employ it efficiently, Altos Labs is poised to accomplish its mission statement, “to restore cell health and resilience to reverse disease, injury, and disabilities that occur throughout life.”



But what does all of this have to do with Genflow Biosciences potentially significant rise in value?

I’m going to tell you, but first, let’s get some background.

Genflow Biosciences is challenging the aging process with exclusive patents to the leading longevity technology from the University of Rochester (US).

Okay, but why should we expect such sudden exponential growth.

The answer lies in a 2013 paper published in a highly regarded journal entitled “The Hallmarks of Ageing”...

To put it simply, the paper outlines 9 hallmarks of aging that provide a framework for prolonging human life. This roadmap to longevity spawned numerous biotech companies that used it as a roadmap for their R&D.



But even the companies regarded as the cream-of-crop are at a disadvantage…

They tend to focus on a single hallmark of aging. To quote Eric Leire, the company’s chief executive, “You’ve only solved one-ninth of the problem with this approach.”

Genflow Biosciences takes a holistic approach by targeting 4 of the 9 hallmarks directly, in addition to 2 indirectly. They are able to do this by focusing on the SIRT6 gene. This gene’s overexpression has proven to extend the lives of healthy mice, winning it the title of the “master regulator of aging”.

This novel research has allowed the company to capture alluring patents, which brings us back to Altos Labs…

If anyone wants this IP they would have to purchase the company at a significant premium to the current share price or enter a licensing agreement.

Altos Labs opened only last year, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition.

It stands to reason that Genflow Biosciences could become an attractive acquisition target for a mega-tech startup such as Altos Labs.

Markets are extremely sensitive to takeovers, and the mere rumour of a potential acquisition could result in a drastic increase in Genflow's significantly undervalued share price



News like this could pop at any second. Launching Genflow Biosciences into the spotlight at any time this year.

This is a highly competitive industry and players with deep pockets see Genflow Biosciences’ IP as their ticket to the top of the market. If it’s not Altos Labs, then surely there will be another.

That is why I am recommending readers take a close look at it right now.

The company is currently eyeing a listing in other markets and a US listing may be on the horizon.



If I were to bet on the next big biotech stock story, Genflow BioSciences would be it.
Posted at 28/11/2022 15:04 by moneymunch
The answer lies in a 2013 paper published in a highly regarded journal entitled “The Hallmarks of Ageing”...

To put it simply, the paper outlines 9 hallmarks of aging that provide a framework for prolonging human life. This roadmap to longevity spawned numerous biotech companies that used it as a roadmap for their R&D.

 

But even the companies regarded as the cream-of-crop are at a disadvantage…

They tend to focus on a single hallmark of aging. To quote Eric Leire, the company’s chief executive, “You’ve only solved one-ninth of the problem with this approach.”

Genflow Biosciences takes a holistic approach by targeting 4 of the 9 hallmarks directly, in addition to 2 indirectly. They are able to do this by focusing on the SIRT6 gene. This gene’s overexpression has proven to extend the lives of healthy mice, winning it the title of the “master regulator of aging”.

This novel research has allowed the company to capture alluring patents, which brings us back to Altos Labs…

If anyone wants this IP they would have to purchase the company at a significant premium to the current share price or enter a licensing agreement.

Altos Labs opened only a few months ago, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition.

It stands to reason that the mega-tech startup would team up with or outright buy Genflow Biosciences, launching its extremely undervalued share price to match, or exceed, its peer group.

Consider that on mere rumors of acquisition for their LIDAR IP, Microvision’s (MVIS) share price exploded almost 300% in less than 2 weeks last year.

Now imagine the sudden news that a Bezo’s backed company set on discovering the formula for immortality is acquiring or partnering with a little-known European biotech start-up with a share price of only 2p

 

News like this could pop at any second. Launching Genflow Biosciences into the spotlight at any time this year.

This is a highly competitive industry and players with deep pockets see Genflow Biosciences’ IP as their ticket to the top of the market. If it’s not Altos Labs, then surely there will be another. 
Genflow Biosciences share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock